Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
The FDA is preparing guidance on generative AI in medical devices, and over 500 stakeholders — from patients to medtech giants — have weighed in. Industry groups want the existing regulatory framework preserved, while physicians and patient advocates are pushing for stronger safeguards and robust postmarket monitoring. The debate centers on a key question: is generative AI a decision-support tool or a decision-maker?
The FDA is gearing up to regulate generative AI in medical devices, and the public comment period has made one thing clear: everyone has an opinion. Following an August discussion paper proposing a physician-credentialing-inspired framework, the agency received more than 500 submissions from patients, clinicians, device makers, and advocacy groups — each with a distinct vision for how AI should be governed in healthcare.
Industry heavyweights like AdvaMed and GE Healthcare want the FDA to stick with its existing regulatory playbook, arguing that generative AI shouldn't automatically trigger new competency assessments. On the other side, patient advocates and physician groups are sounding the alarm on consumer-facing AI chatbots, urging the FDA to strip wellness exemptions from AI companion tools and ensure premarket evidence isn't sidelined in favor of postmarket monitoring.
Key Takeaways:
Why it matters: As generative AI embeds itself deeper into clinical workflows and consumer health apps, the FDA's forthcoming guidance will shape who's accountable when these tools fail — and how much risk patients unknowingly absorb.
